Figure 2
Figure 2. Cumulative incidence and Kaplan-Meier estimates. (A) NRM. Cumulative incidence of NRM in recipients of haploidentical donor, unrelated donor with ATG, and unrelated donor without ATG allo-HCT (overall, P = .08 at 3 years). (B) Relapse/progression. Cumulative incidence of lymphoma relapse/progression in recipients of haploidentical donor, unrelated donor with ATG, and unrelated donor without ATG allo-HCT (overall, P = .07 at 3 years). (C) PFS. Kaplan-Meir estimate of PFS in recipients of haploidentical donor, unrelated donor with ATG, and unrelated donor without ATG allo-HCT (overall, P = .02 at 3 years). (D) OS. Kaplan-Meier estimate of OS in recipients of haploidentical donor, unrelated donor with ATG, and unrelated donor without ATG allo-HCT (overall, P = .02 at 3 years).

Cumulative incidence and Kaplan-Meier estimates. (A) NRM. Cumulative incidence of NRM in recipients of haploidentical donor, unrelated donor with ATG, and unrelated donor without ATG allo-HCT (overall, P = .08 at 3 years). (B) Relapse/progression. Cumulative incidence of lymphoma relapse/progression in recipients of haploidentical donor, unrelated donor with ATG, and unrelated donor without ATG allo-HCT (overall, P = .07 at 3 years). (C) PFS. Kaplan-Meir estimate of PFS in recipients of haploidentical donor, unrelated donor with ATG, and unrelated donor without ATG allo-HCT (overall, P = .02 at 3 years). (D) OS. Kaplan-Meier estimate of OS in recipients of haploidentical donor, unrelated donor with ATG, and unrelated donor without ATG allo-HCT (overall, P = .02 at 3 years).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal